Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

One Down, Two To Go For Adcetris’ Expansion In Lymphoma

Executive Summary

Takeda/Seattle Genetics announced positive Phase III data from the ALCANZA trial evaluating the antibody drug-conjugate in patients with cutaneous T-cell lymphoma (CTCL). Phase III studies in other potentially larger lymphoma indications are ongoing.

Advertisement

Related Content

Mogamulizumab Nips At Adcetris’s Heels In CTCL After New Results
Pivotal ALCANZA Trial Secures Adcetris' Position in Cutaneous Lymphoma
Keeping Track: Mylan Submits Biosimilar Herceptin; FDA Clears Opdivo For Head And Neck Cancer
Bristol’s Opdivo Is First Checkpoint Inhibitor Cleared For Blood Cancer
Seattle Genetics Wins 3rd Indication For Adcetris
Early Adcetris OK no surprise to SGEN after taking US FDA's advice

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097035

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel